Clinical outcomes of eslicarbazepine acetate monotherapy for focal-onset seizures: A multicenter audit.

Abstract

To assess the effectiveness and tolerability of eslicarbazepine acetate (ESL) monotherapy in routine clinical practice for the treatment of focal-onset seizures. Multicenter, retrospective, observational study conducted in patients older than 16years treated with ESL as first-line monotherapy or converted to ESL monotherapy from polytherapy or other monotherapy. Outcomes included 1-year retention rate, seizure-free rates after 6 and 12months of monotherapy treatment, and safety/tolerability issues. A total of 256 patients were included (106 first-line and 150 conversion to monotherapy; 56 patients aged >65years). Overall, the 1-year retention rate was 79% (72.7% in the ≥65years subgroup) and seizure-free rates at 6 and 12months were 59.3% and 55.3% (72.2% and 67.3% in the ≥65years subgroup), without significant differences when comparing first-line vs conversion-to-ESLmonotherapy groups (P=.979). However, the conversion group was heterogeneous and included 43 (29.1%) patients that were seizure free the year prior ESL introduction. A substantially higher proportion of patients remained seizure free for the entire follow-up among those who initiated ESL due to tolerability problems compared with those treated due to inadequate seizure control (71.4% vs 37.3%). Overall, 62 of 256 (24.2%) patients reported AEs (39.3% in >65years subgroup) and led to discontinuation in 20/256 (7.8%) patients (12.5% in >65years subgroup). Commonly reported AEs were somnolence (6.6%), dizziness (6.3%), and headache (4.3%). Hyponatremia was recorded in five patients, the majority (4/5) of whom were older than 65years. Eslicarbazepine acetate was effective and well-tolerated as first-line or conversion to monotherapy in a clinical setting in adult and elderly patients with focal-onset seizures.